Pfizer’s Shedlarz To Retire By Year End
This article was originally published in The Pink Sheet Daily
Departure of Shedlarz follows several other high-profile exits since CEO Kindler took the helm last year.
You may also be interested in...
R&D head LaMattina and CFO Levin have 50 years of experience with Pfizer between them.
New CEO Jeffrey Kindler also establishes a seven member "Executive Leadership Team."
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.